Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PPI 1011

Drug Profile

PPI 1011

Alternative Names: Ethanolamine plasmalogen precursor - Phenomenome Discoveries; Ether glycerophosphoethanolamine lipid precursor - Phenomenome Discoveries; Ether lipid precursor - Phenomenome Discoveries; PlsEtn precursor - Phenomenome Discoveries; PPI-1011

Latest Information Update: 03 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Phenomenome Discoveries
  • Developer GraySpace Therapeutics; Phenomenome Discoveries
  • Class 1 ring heterocyclic compounds; Esters; Ethers; Omega 3 fatty acids; Plasmalogens
  • Mechanism of Action Plasmalogen replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Rhizomelic chondrodysplasia punctata
  • Preclinical Alzheimer's disease; Dyskinesias; Parkinson's disease
  • Discontinued Pelizaeus-Merzbacher disease

Most Recent Events

  • 29 May 2023 Phase-I clinical trials in Rhizomelic chondrodysplasia punctata in Canada (PO) (NCT05969977)
  • 03 Jan 2023 Chemical structure information added
  • 28 Dec 2022 PPI 1011 is still in preclinical trials in Alzheimer's disease in Canada (PO) as of December 2022 (GraySpace Therapeutics website, December 2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top